OncoMatch/Clinical Trials/NCT04616209
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Is NCT04616209 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies donor-derived NK cell infusion for non-small cell lung cancer.
Treatment: donor-derived NK cell infusion — Objectives: To determine the safety, tolerability, and efficacy of allogeneic PB103 in patients with IIIb/IV or refractory non-small-cell lung cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IIIB, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy to the lung fields
Patients who have had radiation to the lung fields within four weeks of starting treatment
Lab requirements
Blood counts
ANC ≥ 1500 cells/mm3; Platelet count ≥ 75,000 cells/mm3; Hgb ≥ 9.0 g/dL
Kidney function
Estimated GFR ≥ 60 ml/min /1.73m2 or creatinine clearance ≥ 60 mL/min
Liver function
AST and ALT ≤ 3.0 × ULN (≤ 5× ULN if hepatic metastases); total serum bilirubin ≤ 1.5 × ULN
Acceptable organ function, as evidenced by the following laboratory data: (a) AST and ALT ≤ 3.0 × ULN (≤ 5× ULN if hepatic metastases) (b) Total serum bilirubin ≤ 1.5 × ULN (c) ANC ≥ 1500 cells/mm3 (d) Platelet count ≥ 75,000 cells/mm3 (e) Hgb ≥ 9.0 g/dL (f) Estimated GFR ≥ 60 ml/min /1.73m2 or creatinine clearance ≥ 60 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify